Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06391125 · ClinicalTrials.gov registry record · Phase 3

LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment

A Phase 3 study of Syphilis Infection and Benzathine Penicillin Adverse Reaction, sponsored by Washington University School of Medicine.

Recruiting
Registry status
Phase 3
Development phase
48
Enrollment target
1
Study location

NCT06391125 is a Phase 3 study of Syphilis Infection and Benzathine Penicillin Adverse Reaction that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06391125, a Phase 3 study of Syphilis Infection and Benzathine Penicillin Adverse Reaction, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
Phase 3
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

There is evidence to suggest that lidocaine can help reduce the pain associated with intramuscular injections of benzathine penicillin G (BPG) or Bicillin, used to treat syphilis infections. A study published in the Journal of Family Practice in 2001 compared the pain experienced during bicillin injections with and without the use of lidocaine. The study found that patients who received lidocaine injections before receiving bicillin reported significantly less pain compared to those who received bicillin injections without lidocaine. Per the International Union against Sexually Transmitted Infections (IUSTI) European Guidelines for syphilis management, lidocaine has been used as a diluent for BPG since 1998. In the United States (US), BPG often comes prepackaged and lidocaine is unable to be used as a diluent with the same ease as it is in Europe. In light of this, the investigators propose a randomized controlled trial of benzathine penicillin G with and without lidocaine to quantify any site pain reduction with lidocaine in patients being treated for syphilis. This study is a randomized, double blinded, placebo controlled trial. During this study, patients needing BPG treatment for syphilis will be screened for any penicillin allergies and consented to their participation. Each participant will receive 2 injections of BPG, 1.2 million units each (2x1.2 million units = 2.4 million units, the standard dose for syphilis treatment), as intramuscular injections, one in each gluteal muscle, with one of the injections randomly having 0.5ml of 1% lidocaine added while the other has 0.5 ml normal saline solution. The side of each injection will be randomized by the medical assistant (MA)/nurse filling the vials and the injecting MA will be blinded, as well as the study participant, as to which vial contains lidocaine and which contains normal saline. The participants will then be asked to rate their pain from 0-10 on each site of injection at 10 minutes post injection, th

Interventions

  • DRUG Lidocaine
  • DRUG normal Saline

Study Locations (1)

Missouri

  • WashU Infectious Diseases Clinic - St Louis

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2024-07-01
Est. Completion 2025-12
Phase Phase 3

What the Registry Record Tells You About NCT06391125

The ClinicalTrials.gov registry entry for NCT06391125 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Syphilis Infection appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine is the first listed.

NCT06391125 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT06391125 about?

NCT06391125 is a clinical study titled "LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment". There is evidence to suggest that lidocaine can help reduce the pain associated with intramuscular injections of benzathine penicillin G (BPG) or Bicillin, used to treat syphilis infections. A study published in the Journal of Family Practice in 2001 compared the pain experienced during bicillin inj...

What is the current status of trial NCT06391125?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2024-07-01. Estimated completion is 2025-12.

What conditions does trial NCT06391125 study?

This clinical trial studies the following conditions: Syphilis Infection, Benzathine Penicillin Adverse Reaction.

What interventions are being tested in trial NCT06391125?

The interventions under investigation include: Lidocaine (DRUG), normal Saline (DRUG).

Who is sponsoring clinical trial NCT06391125?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06391125 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.